Optimization of a privileged structure leading to potent and selective human melanocortin subtype-4 receptor ligands.
Design and synthesis of potent MC4 selective agonists based on cyclohexylpiperidine derived cyclic urea, oxazolidinones, and sulfonamide based privileged structures are disclosed.